Abstract

The ability to elicit broadly neutralizing antibody responses against HIV-1 is a crucial goal for a prophylactic HIV-1 vaccine. Here, we discuss the difficulties of achieving broad HIV-1 neutralization in the context of both the effective annual human influenza virus vaccine and the need to develop a pandemic influenza vaccine. Immunogen-design strategies are underway to target functionally conserved regions of the HIV-1 envelope glycoproteins, and similar strategies might be applicable to pandemic influenza virus vaccine development. Efforts to develop broadly neutralizing vaccines against either HIV-1 or influenza virus might establish a paradigm for future vaccines against highly variable pathogens.

Author affiliations

1. Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden, and Swedish Institute for Infectious Disease Control, 171 82 Solna, Sweden.
2. National Influenza Center and Department of Virology, Erasmus Medical Center, 3015GE Rotterdam, Netherlands.
3. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
4. Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
5. Department of Cancer Immunology & AIDS, Dana–Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, Maryland 02115, USA.

Correspondence to: Richard T. Wyatt³ Email: richardwyatt@nih.gov

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.